Irene Nowotny

Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist

Martin Bossart, Michael Wagner, Ralf Elvert et al. · Cell Metabolism · 2021 · 170 citations · Full text

Medicine, Endocrinology, Pharmacology +17

Low within‐ and between‐day variability in exposure to new insulin glargine 300 U/ml

R. H. A. Becker, Irene Nowotny, Lenore Teichert et al. · Diabetes Obesity and Metabolism · 2014 · 125 citations · Full text

Pharmacy, Endocrinology, Pharmacology +16

Levofloxacin in the empirical treatment of patients with suspected bacteraemia/sepsis: comparison with imipenem/cilastatin in an open, randomized trial

A. Geddes, Michael Thaler, S Schönwald et al. · Journal of Antimicrobial Chemotherapy · 1999 · 33 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +15

Similar pharmacokinetics and pharmacodynamics of rapid‐acting insulin lispro products <scp>SAR342434</scp> and <scp>US</scp> ‐ and <scp>EU</scp> ‐approved Humalog in subjects with type 1 diabetes

Christoph Kapitza, Irene Nowotny, Anne Lehmann et al. · Diabetes Obesity and Metabolism · 2016 · 28 citations

Medicine, Clinical Pharmacokinetics, Pharmacology +16

Single-Dose Euglycemic Clamp Study Demonstrating Pharmacokinetic and Pharmacodynamic Similarity Between SAR341402 Insulin Aspart and US- and EU-Approved Versions of Insulin Aspart in Subjects with Type 1 Diabetes

Christoph Kapitza, Leszek Nosek, Wolfgang Schmider et al. · Diabetes Technology & Therapeutics · 2019 · 18 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +12